Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 18, Pages -Publisher
MDPI
DOI: 10.3390/ijms231810706
Keywords
cutaneous lupus erythematosus; systemic lupus erythematosus; immune cells; treatments
Funding
- FONDECYT [1070352, 1190830, 11200764, 1191300]
- FONDEF [D11I1080]
- PAI ANID [SA77210051]
- Millennium Institute on Immunology and Immunotherapy ANID [ACE 210015, CN09_016/ICN 2021_045]
Ask authors/readers for more resources
CLE is an autoimmune disorder characterized by autoantibody secretion and immune cell recruitment, similar to SLE. It can be divided into different types with varying severity of skin lesions. Type I IFN plays a significant role in the development of CLE. Research aims to develop effective treatments.
Cutaneous lupus erythematosus (CLE) is an autoimmune disorder like systemic lupus erythematosus (SLE). Both SLE and CLE characterize autoantibody secretion and immune cell recruitment. In particular, CLE can be divided into three more frequent types, varying in the severity of the skin lesions they present. The role of type I IFN was shown to be one of the leading causes of the development of this pathology in the skin. Different treatments have been developed and tested against these different variants of CLE to decrease the increasing levels of CLE in humans. In this article, a literature revision discussing the similarities between SLE and CLE is carried out. In addition, new advances in understanding the development of CLE and the leading treatments being evaluated in animal models and clinical trials are reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available